Saltar para: Post [1], Pesquisa e Arquivos [2]


Noticias de Crohn - Copy.png

Resumo na língua original:

The independent Data and Safety Monitoring Board has unanimously recommended the continuation of the phase 3 MAP US study evaluating RHB-104, an investigative oral antibiotic therapy for Crohn’s disease, according to RedHill Biopharma, who remains blinded to the data.


RHB-104 is a “potentially groundbreaking” oral antibiotic combination therapy with intracellular, antimycobacterial and anti-inflammatory properties that targets Mycobacterium avium subspecies paratuberculosis (MAP), a bacterial infection and a suspected cause of Crohn’s disease, according to a press release.





Ler artigo original


Autoria e outros dados (tags, etc)

publicado às 17:28


  Pesquisar no Blog

Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.

Posts mais comentados